Antiviral therapy in chronic hepatitis B viral infection during pregnancy: A systematic review and meta-analysis

Hepatology

Volumn 63, Issue 1, 2016, Pages 319-333

  Brown, Robert S ^a   Mcmahon, Brian J ^b   Lok, Anna S F ^c   Wong, John B ^d   Ahmed, Ahmed T ^e   Mouchli, Mohamed A ^e   Wang, Zhen ^e   Prokop, Larry J ^e   Murad, Mohammad Hassan ^e   Mohammed, Khaled ^e  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b ALASKA NATIVE TRIBAL HEALTH CONSORTIUM   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

^d TUFTS MEDICAL CENTER   (United States)

^e MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE KINASE; DNA; ENTECAVIR; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; TELBIVUDINE; TENOFOVIR; ANTIVIRUS AGENT;

ADVERSE OUTCOME; ANTIVIRAL THERAPY; APGAR SCORE; ARTICLE; CESAREAN SECTION; CHRONIC HEPATITIS B; CLINICAL PROTOCOL; COMPARATIVE STUDY; CONGENITAL MALFORMATION; DISEASES; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; EVIDENCE BASED PRACTICE; FEMALE; FETUS OUTCOME; FOLLOW UP; HEPATITIS B VIRUS; HUMAN; LABOR INDUCTION; LIVER DISEASE; META ANALYSIS (TOPIC); MOTHER TO CHILD TRANSMISSION; OUTCOME ASSESSMENT; PATIENT SAFETY; POSTPARTUM HEMORRHAGE; PREGNANCY; PREGNANT WOMAN; PREMATURITY; PRIORITY JOURNAL; PUERPERIUM; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SYSTEMATIC REVIEW; VACCINATION; VIRUS LOAD; VIRUS TRANSMISSION; HEPATITIS B, CHRONIC; META ANALYSIS; NEWBORN; PREGNANCY COMPLICATIONS, INFECTIOUS; PREGNANCY OUTCOME;

ANTIVIRAL AGENTS; FEMALE; HEPATITIS B, CHRONIC; HUMANS; INFANT, NEWBORN; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREGNANCY OUTCOME;

EID: 84951761513     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.28302     Document Type: Article

References (56)

1. Maynard JE. Hepatitis B: global importance and need for control. Vaccine 1990;8(Suppl.):S18-20; S21-13.
2. Beasley RP, Hwang LY, Lin CC, Leu ML, Stevens CE, Szmuness W, et al. Incidence of hepatitis B virus infections in preschool children in Taiwan. J Infect Dis 1982;146:198-204.
3. Alter MJ, Hadler SC, Margolis HS, Alexander WJ, Hu PY, Judson FN, et al. The changing epidemiology of hepatitis B in the United States. Need for alternative vaccination strategies. JAMA 1990;263:1218-1222.
4. Stevens CE, Beasley RP, Tsui J, Lee WC. Vertical transmission of hepatitis B antigen in Taiwan. N Engl J Med 1975;292:771-774.
5. Lok AS, Lai CL, Wu PC, Leung EK, Lam TS. Spontaneous hepatitis B e antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection. Gastroenterology 1987;92:1839-1843.
6. Lok AS, Lai CL. A longitudinal follow-up of asymptomatic hepatitis B surface antigen-positive Chinese children. Hepatology 1988;8:1130-1133.
7. Liaw YF, Chu CM, Lin DY, Sheen IS, Yang CY, Huang MJ. Age-specific prevalence and significance of hepatitis B e antigen and antibody in chronic hepatitis B virus infection in Taiwan: a comparison among asymptomatic carriers, chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma. J Med Virol 1984;13:385-391.
8. Stevens CE, Toy PT, Tong MJ, Taylor PE, Vyas GN, Nair PV, et al. Perinatal hepatitis B virus transmission in the United States. Prevention by passive-active immunization. JAMA 1985;253:1740-1745.
9. Livingston SE, Simonetti JP, Bulkow LR, Homan CE, Snowball MM, Cagle HH, et al. Clearance of hepatitis B e antigen in patients with chronic hepatitis B and genotypes A, B, C, D, and F. Gastroenterology 2007;133:1452-1457.
10. Wiseman E, Fraser MA, Holden S, Glass A, Kidson BL, Heron LG, et al. Perinatal transmission of hepatitis B virus: an Australian experience. Med J Aust 2009;190:489-492.
11. Burk RD, Hwang LY, Ho GY, Shafritz DA, Beasley RP. Outcome of perinatal hepatitis B virus exposure is dependent on maternal virus load. J Infect Dis 1994;170:1418-1423.
12. Li XM, Shi MF, Yang YB, Shi ZJ, Hou HY, Shen HM, et al. Effect of hepatitis B immunoglobulin on interruption of HBV intrauterine infection. World J Gastroenterol 2004;10:3215-3217.
13. Zou H, Chen Y, Duan Z, Zhang H, Pan C. Virologic factors associated with failure to passive-active immunoprophylaxis in infants born to HBsAg-positive mothers. J Viral Hepat 2012;19:e18-25.
14. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009;50:661-662.
15. Tenney DJ, Rose RE, Baldick CJ, Pokornowski KA, Eggers BJ, Fang J, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 2009;49:1503-1514.
16. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006;131:1743-1751.
17. Chang TT, Liaw YF, Wu SS, Schiff E, Han KH, Lai CL, et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 2010;52:886-893.
18. Schiff ER, Lee SS, Chao YC, Kew Yoon S, Bessone F, Wu SS, et al. Long-term treatment with entecavir induces reversal of advanced fibrosis or cirrhosis in patients with chronic hepatitis B. Clin Gastroenterol Hepatol 2011;9:274-276.
19. Shi Z, Yang Y, Ma L, Li X, Schreiber A. Lamivudine in late pregnancy to interrupt in utero transmission of hepatitis B virus: a systematic review and meta-analysis. Obstet Gynecol 2010;116:147-159.
20. Brown RS Jr, Verna EC, Pereira MR, Tilson HH, Aguilar C, Leu CS, et al. Hepatitis B virus and human immunodeficiency virus drugs in pregnancy: findings from the Antiretroviral Pregnancy Registry. J Hepatol 2012;57:953-959.
21. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. Open Med 2009;3:e123-e130.
22. Murad MH, Montori VM, Ioannidis JP, Jaeschke R, Devereaux PJ, Prasad K, et al. How to read a systematic review and meta-analysis and apply the results to patient care: users' guides to the medical literature. JAMA 2014;312:171-179.
23. Sterne JA, Sutton AJ, Ioannidis JP, Terrin N, Jones DR, Lau J, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ 2011;343:d4002.
24. Han L, Zhang HW, Xie JX, Zhang Q, Wang HY, Cao GW. A meta-analysis of lamivudine for interruption of mother-to-child transmission of hepatitis B virus. World JGastroenterol 2011;17:4321-4333.
25. Lu YP, Liang XJ, Xiao XM, Huang SM, Liu ZW, Li J, et al. Telbivudine during the second and third trimester of pregnancy interrupts HBV intrauterine transmission: a systematic review and meta-analysis. Clin Lab 2014;60:571-586.
26. Zhang L-j, Wang L. Blocking intrauterine infection by telbivudine in pregnant chronic hepatitis B patients. [in Chinese] Chung Hua Kan Tsang Ping Tsa Chih 2009;17:561-563.
27. Xu WM, Cui YT, Wang L, Yang H, Liang ZQ, Li XM, et al. Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebo-controlled study. J Viral Hepat 2009;16:94-103.
28. Yang S, Liu M, Wang L. Effect of high viral hepatitis B virus DNA loads on vertical transmission of hepatitis B virus in late-pregnant women. [in Chinese] Zhonghua Fu Chan Ke Za Zhi 2008;43:329-331.
29. Li X-M, Yang Y-B, Hou H-Y, Shi Z-J, Shen H-M, Teng B-Q, et al. Interruption of HBV intrauterine transmission: a clinical study. World J Gastroenterol 2003;9:1501-1503.
30. Zhang YF. The clinical observation of effect of lamivudine on interrupting mother to infant transmission of chronic HBV on 50 mothers. [in Chinese] J Pract Obstet Gynecol 2010;26:367-368.
31. Shi ZJ, Yang YB, Ma L. Clinical research on the interruption of mother to child transmission of HBV-a randomized, double-blind, placebo-control study. Presented at: 6th Annual Global Health Conference; April 18-19, 2009; New Haven, CT.
32. Guo YZ, Ge SL, Wang JH. Effect of lamivudine treatment combined with active-passive immunization on interrupting mother to infant transmission of HBV. [in Chinese] Clin Focus 2008;23:1730-1731.
33. Xiang GJ, Sun JW, Jiang SQ, Hu XB, Qu AL. Evaluation of therapeutic effect in HBV vertical transmission by lamivudine treatment combined with active-passive immunization for pregnant women. [in Chinese] Chin Prac Med 2007;2:14-16.
34. Shi MF, He J, Yang YB, Hou HY, Zhuang YL, Shen HM. Study of lamivudine in interruption of HBV intrauterine infection. [in Chinese] Clin Med Chin 2005;21:77-78.
35. Guo HJ. Observation the role of telbivudine in blocking mother-to-child transmission of HBV in pregnant women with high viral load. Journal of Changzhl Medical College 2011;25:368-370.
36. Zhang H, Pan CQ, Pang Q, Tian R, Yan M, Liu X. Telbivudine or lamivudine use in late pregnancy safely reduces perinatal transmission of hepatitis B virus in real-life practice. Hepatology 2014;60:468-476.
37. Greenup A-J, Tan PK, Nguyen V, Glass A, Davison S, Chatterjee U, et al. Efficacy and safety of tenofovir disoproxil fumarate in pregnancy to prevent perinatal transmission of hepatitis B virus. J Hepatol 2014;61:502-507.
38. Celen MK, Mert D, Ay M, Dal T, Kaya S, Yildirim N, et al. Efficacy and safety of tenofovir disoproxil fumarate in pregnancy for the prevention of vertical transmission of HBV infection. World J Gastroenterol 2013;19:9377-9382.
39. + chronic hepatitis B. [in Chinese] Zhonghua Fu Chan Ke Za Zhi 2012;20:888-891.
40. Chen R, Liu S-r, Zhang S-y, Tao C-j. Efficacy of telbivudine in blocking the vertical transmission and the safety observation of discontinuing treatment time after delivery on mother infected with HBV. [in Chinese] Zhonghua Fu Chan Ke Za Zhi 2012;20:703-704.
41. Yu M, Jiang Q, Ji Y, Jiang H, Wu K, Ju L, et al. The efficacy and safety of antiviral therapy with lamivudine to stop the vertical transmission of hepatitis B virus. Eur J Clin Microbiol Infect Dis 2012;31:2211-2218.
42. Pan CQ, Han G-R, Jiang H-X, Zhao W, Cao M-K, Wang C-M, et al. Telbivudine prevents vertical transmission from HBeAg-positive women with chronic hepatitis B. Clin Gastroenterol Hepatol 2012;10:520-526.
43. Han G-r, Jiang H-x, Wang G-j, Yue X, Wang C-m, Kan N-y, et al. Efficacy and safety of telbivudine in pregnant women to prevent perinatal transmission of hepatitis B virus. [in Chinese] Zhonghua Fu Chan Ke Za Zhi 2012;20:201-205.
44. Han G-R, Cao M-K, Zhao W, Jiang H-X, Wang C-M, Bai S-F, et al. A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection. J Hepatol 2011;55:1215-1221.
45. Feng HF. Effect on interruption of hepatitis B virus vertical transmission by lamivudine. [in Chinese] J Appl Clin Pediatr 2007;22:1019-1020.
46. Li WF, Jiang R, Wei Z, Li Y. Clinical effect and safety of lamivudine in interruption of chronic HBV maternal to infant transmission. [in Chinese] Chin Hepatol 2006;11:106-107.
47. Han ZH, Chen YH, Li LW, Sun XW, Sun YG, Zhao H, et al. Effect and safety of preventing HBV vertical transmission by lamivudine treatment. [in Chinese] Chin J Intern Med 2005;44:378.
48. Yao ZC, Liao WY, et al. The efficacy and safety of telbivudine in blocking intrauterine hepatitis B viral transmission. J Clin Hepatol 2011;14:259-261.
49. Zhang YF. Efficacy and safety of telbivudin in preventing mother-to-infant HBV tranmission. Adverse Drug Reactions 2010;12:157-159.
50. Chen HL, Lee CN, Chang CH, Ni YH, Shyu MK, Chen SM, et al. Efficacy of maternal tenofovir disoproxil fumarate in interrupting mother-to-infant transmission of hepatitis B virus. Hepatology 2015;62:375-386.
51. Yu M-M, Jiang Q, Ji Y, Wu K-H, Ju L-L, Tang X, et al. Comparison of telbivudine versus lamivudine in interrupting perinatal transmission of hepatitis B virus. J Clin Virol 2014;61:55-60.
52. Siberry GK, Jacobson DL, Kalkwarf HJ, Wu JW, DiMeglio LA, Yogev R, et al. Lower newborn bone mineral content associated with maternal use of tenofovir disoproxil fumarate during pregnancy. Clin Infect Dis 2015;61:996-1003.
53. Siberry GK, Williams PL, Mendez H, Seage GR 3rd, Jacobson DL, Hazra R, et al. Safety of tenofovir use during pregnancy: early growth outcomes in HIV-exposed uninfected infants. AIDS 2012;26:1151-1159.
54. Lok AS, Lai CL, Leung N, Yao GB, Cui ZY, Schiff ER, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003;125:1714-1722.
55. Heathcote EJ, Marcellin P, Buti M, Gane E, De Man RA, Krastev Z, et al. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology 2011;140:132-143.
56. Terrault N, Chang K-M, Hwang J, Jonas M, Murad H. AASLD guidelines for treatment of chronic hepatitis B. Hepatology 2015;63:261-283. http://onlinelibrary.wiley.com/doi/10.1002/hep.28156/full.